查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
毒系药物的全球市场 - 产业规模，占有率，趋势，机会，预测:各动物类型，各来源，各治疗领域，各企业，各地区(2017年～2027年)
市场调查报告书
商品编码
1166587

毒系药物的全球市场 - 产业规模，占有率，趋势，机会，预测:各动物类型，各来源，各治疗领域，各企业，各地区(2017年～2027年)

Venom Based Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Animal Type, By Source, By Therapeutic Area, By Company and By Region
出版日期: | 出版商: TechSci Research | 英文 116 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球毒系药物市场，预计从2023年到2027年的预测期间内完成惊人的成长。主要原因，是各种疾病的发生率增加，由于政府及民间组织的配合措施增加等，促进市场成长。支撑市场成长的其他因素，是广泛的研究开发，多数的临床试验，认识度的提高，政府的投资，多数的有毒动物，毒系新药的认证的容易度，及这个领域的技术进步。

本报告提供全球毒系药物市场相关调查，各市场区隔分析，市场动态，企业简介等资讯。

目录

第1章 产品概要

第2章 调查手法

第3章 COVID-19对全球毒系药物市场的影响

第4章 摘要整理

第5章 VOC (客户的迴响)

  • 使用毒系药物的优点
  • 为了製造毒系药物一般使用的动物
  • 毒系药物的需求:各治疗领域
  • 对毒系药物的引进的障碍

第6章 FDA的毒系认证核可药的清单

第7章 临床试验分析

第8章 全球毒系药物市场预测

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各动物类型(蛇，蜘蛛，蜂，其他)
    • 各来源(全毒，合成，重组，其他)
    • 各治疗领域(高血压，心血管疾病，神经疾病，疼痛管理、关节炎，其他)
    • 各企业(2021年)
    • 各地区
  • 市场地图

第9章 北美的毒系药物市场预测

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各动物类型
    • 各来源
    • 各治疗领域
    • 各国
  • 北美:各国分析
    • 美国
    • 墨西哥
    • 加拿大

第10章 欧洲的毒系药物市场预测

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各动物类型
    • 各来源
    • 各治疗领域
    • 各国
  • 欧洲:各国分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第11章 亚太地区的毒系药物市场预测

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各动物类型
    • 各来源
    • 各治疗领域
    • 各国
  • 亚太地区:各国分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第12章 南美的毒系药物市场预测

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各动物类型
    • 各来源
    • 各治疗领域
    • 各国
  • 南美:各国分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第13章 中东、非洲的毒系药物市场预测

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各动物类型
    • 各来源
    • 各治疗领域
    • 各国
  • 中东、非洲:各国分析
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国

第14章 市场动态

  • 促进因素
  • 课题

第15章 市场趋势与发展

第16章 竞争情形

  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Pentapharm Limited
  • Medicure Inc
  • Millennium Pharmaceuticals, Inc.
  • Bausch Health Companies, Inc.
  • Novartis AG
  • Elan Pharmaceuticals, Inc.
  • Beijing Tobishi Pharmaceutical Co., Ltd.

第17章 策略性建议

简介目录
Product Code: 13015

The global venom-based drugs market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing incidences of various diseases, and rise in initiatives by government and private organizations, which are curbing the growth of the market. Venom is a compound which is secreted by an animal. It is a poisonous compound which intended to harm or disable their prey or enemy. When venom is produced through organisms, it includes variety of bioactive components which produce toxic effects. Only those active components of these venoms are isolated, purified, and screened which may have desirable therapeutic properties. The other factors supporting the market's growth are, the extensive research and development, large number of clinical trials, increasing awareness, and government investments, large number of venomous animals, ease in approval of new venom-based drugs, and technological advancements in this field.

Increasing Use of Venom in Numerous Diseases

Venom derived drugs are very useful in treating various diseases such as cancer, heart attack, hypertension, acute coronary syndrome, and other, due to their potential therapeutic values, which propels the growth of the market. Several venom-based drugs are already in use such as captopril, integrilin, reptilase, exanta and others. Moreover, these venom-based drugs are used as diagnostic tools, cosmeceuticals and for drug discovery. For instance, in 2020, a study concluded that bee venom therapy might be useful in treating inflammatory forms of arthritis. Similarly, captopril is a type of drug used to cure high blood pressure and reduce the risk of heart failure after a heart attack. It is derived from a species of pit viper which is found in Brazil.

Technological Advancements and Rise in R&D activities

Owing to rising number of patients suffering from variety of diseases, the surge in demand for the treatment, is augmenting the growth of the market, globally. Various R&D activities are carried by researchers in order to treat these diseases using venom from various animals. The toxins from venom such as proteins, peptides, carbohydrates, and other components are important research tools. Subsequently, other reasons that make animal venoms attractive to researchers across the globe are the specialization, richness, and efficiency of the components present. Also, advancement in genomics, transcriptions and proteomics helps in study of these toxins, which further aids scientists to understand the venoms and their target. For instance, tozuleristide, a diagnostic drug obtained from the venom of the Israeli deathstalker scorpion, is now in clinical trials. An element of the venom, called chlorotoxin, binds to tumor cells. Researchers at the Fred Hutchinson Cancer Research Center re-engineered this protein and attached a fluorescent tag to it, resulting in a diagnostic tool that seeks out and illuminates tumors.

Market Segmentation

The global venom-based drugs market is segmented into animal type, source, therapeutic area, and company. Based on animal type, the market is divided into snake, spider, bee, and others. Based on source, the market is divided into whole venom, synthetic, recombinant, and others. Based on therapeutic area, the market is segmented into hypertension, cardiovascular diseases, neurological disorders, pain management & arthritis, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to extensive research and development on venom based drugs in the country.

Market Players

AstraZeneca Plc., Bristol-Myers Squibb Company, Merck & Co., Inc., Pentapharm Limited Medicure Inc, Millennium Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Elan Pharmaceuticals, Inc., and Beijing Tobishi Pharmaceutical Co., Ltd. are some of the leading companies operating in the market.

Report Scope:

In this report, global venom based drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Venom Based Drugs Market, By Animal Type:

Snake

Spider

Bee

Others

  • Venom Based Drugs Market, By Source:

Whole Venom

Synthetic

Recombinant

Others

  • Venom Based Drugs Market, By Therapeutic Area:

Hypertension

Cardiovascular Diseases

Neurological Disorders

Pain Management & Arthritis

Others

  • Venom Based Drugs Market, By Region:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

Japan

Australia

South Korea

Europe & CIS

Germany

France

United Kingdom

Spain

Italy

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Venom Based Drugs Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Venom Based Drugs Market

4. Executive Summary

5. Voice of Customer

  • 5.1. Benefits of Using Venom Based Drugs
  • 5.2. Commonly Used Animals for Deriving Venom Based Drugs
  • 5.3. Demand for Venom Based Drugs, By Therapeutic Area
  • 5.4. Barriers to Adoption of Venom Based Drugs

6. List of Venom Based Approved Drugs by the FDA

7. Clinical Trials Analysis

8. Global Venom Based Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Animal Type (Snake, Spider, Bee, Others)
    • 8.2.2. By Source (Whole Venom, Synthetic, Recombinant, Others)
    • 8.2.3. By Therapeutic Area (Hypertension, Cardiovascular Diseases, Neurological Disorders, Pain Management & Arthritis, Others)
    • 8.2.4. By Company (2021)
    • 8.2.5. By Region
  • 8.3. Market Map

9. North America Venom Based Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Animal Type
    • 9.2.2. By Source
    • 9.2.3. By Therapeutic Area
    • 9.2.4. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Venom Based Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Animal Type
        • 9.3.1.2.2. By Source
        • 9.3.1.2.3. By Therapeutic Area
    • 9.3.2. Mexico Venom Based Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Animal Type
        • 9.3.2.2.2. By Source
        • 9.3.2.2.3. By Therapeutic Area
    • 9.3.3. Canada Venom Based Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Animal Type
        • 9.3.3.2.2. By Source
        • 9.3.3.2.3. By Therapeutic Area

10. Europe Venom Based Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Animal Type
    • 10.2.2. By Source
    • 10.2.3. By Therapeutic Area
    • 10.2.4. By Country
  • 10.3. Europe: Country Analysis
    • 10.3.1. France Venom Based Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Animal Type
        • 10.3.1.2.2. By Source
        • 10.3.1.2.3. By Therapeutic Area
    • 10.3.2. Germany Venom Based Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Animal Type
        • 10.3.2.2.2. By Source
        • 10.3.2.2.3. By Therapeutic Area
    • 10.3.3. United Kingdom Venom Based Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Animal Type
        • 10.3.3.2.2. By Source
        • 10.3.3.2.3. By Therapeutic Area
    • 10.3.4. Italy Venom Based Drugs Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Animal Type
        • 10.3.4.2.2. By Source
        • 10.3.4.2.3. By Therapeutic Area
    • 10.3.5. Spain Venom Based Drugs Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Animal Type
        • 10.3.5.2.2. By Source
        • 10.3.5.2.3. By Therapeutic Area

11. Asia-Pacific Venom Based Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Animal Type
    • 11.2.2. By Source
    • 11.2.3. By Therapeutic Area
    • 11.2.4. By Country
  • 11.3. Asia-Pacific: Country Analysis
    • 11.3.1. China Venom Based Drugs Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Animal Type
        • 11.3.1.2.2. By Source
        • 11.3.1.2.3. By Therapeutic Area
    • 11.3.2. India Venom Based Drugs Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Animal Type
        • 11.3.2.2.2. By Source
        • 11.3.2.2.3. By Therapeutic Area
    • 11.3.3. Japan Venom Based Drugs Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Animal Type
        • 11.3.3.2.2. By Source
        • 11.3.3.2.3. By Therapeutic Area
    • 11.3.4. South Korea Venom Based Drugs Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Animal Type
        • 11.3.4.2.2. By Source
        • 11.3.4.2.3. By Therapeutic Area
    • 11.3.5. Australia Venom Based Drugs Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Animal Type
        • 11.3.5.2.2. By Source
        • 11.3.5.2.3. By Therapeutic Area

12. South America Venom Based Drugs Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Animal Type
    • 12.2.2. By Source
    • 12.2.3. By Therapeutic Area
    • 12.2.4. By Country
  • 12.3. South America: Country Analysis
    • 12.3.1. Brazil Venom Based Drugs Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Animal Type
        • 12.3.1.2.2. By Source
        • 12.3.1.2.3. By Therapeutic Area
    • 12.3.2. Argentina Venom Based Drugs Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Animal Type
        • 12.3.2.2.2. By Source
        • 12.3.2.2.3. By Therapeutic Area
    • 12.3.3. Colombia Venom Based Drugs Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Animal Type
        • 12.3.3.2.2. By Source
        • 12.3.3.2.3. By Therapeutic Area

13. Middle East and Africa Venom Based Drugs Market Outlook

  • 13.1. Market Size & Forecast
    • 13.1.1. By Value
  • 13.2. Market Share & Forecast
    • 13.2.1. By Animal Type
    • 13.2.2. By Source
    • 13.2.3. By Therapeutic Area
    • 13.2.4. By Country
  • 13.3. MEA: Country Analysis
    • 13.3.1. South Africa Venom Based Drugs Market Outlook
      • 13.3.1.1. Market Size & Forecast
        • 13.3.1.1.1. By Value
      • 13.3.1.2. Market Share & Forecast
        • 13.3.1.2.1. By Animal Type
        • 13.3.1.2.2. By Source
        • 13.3.1.2.3. By Therapeutic Area
    • 13.3.2. Saudi Arabia Venom Based Drugs Market Outlook
      • 13.3.2.1. Market Size & Forecast
        • 13.3.2.1.1. By Value
      • 13.3.2.2. Market Share & Forecast
        • 13.3.2.2.1. By Animal Type
        • 13.3.2.2.2. By Source
        • 13.3.2.2.3. By Therapeutic Area
    • 13.3.3. UAE Venom Based Drugs Market Outlook
      • 13.3.3.1. Market Size & Forecast
        • 13.3.3.1.1. By Value
      • 13.3.3.2. Market Share & Forecast
        • 13.3.3.2.1. By Animal Type
        • 13.3.3.2.2. By Source
        • 13.3.3.2.3. By Therapeutic Area

14. Market Dynamics

  • 14.1. Drivers
  • 14.2. Challenges

15. Market Trends & Developments

16. Competitive Landscape

  • 16.1. AstraZeneca Plc.
  • 16.2. Bristol-Myers Squibb Company
  • 16.3. Merck & Co., Inc.
  • 16.4. Pentapharm Limited
  • 16.5. Medicure Inc
  • 16.6. Millennium Pharmaceuticals, Inc.
  • 16.7. Bausch Health Companies, Inc.
  • 16.8. Novartis AG
  • 16.9. Elan Pharmaceuticals, Inc.
  • 16.10. Beijing Tobishi Pharmaceutical Co., Ltd.

17. Strategic Recommendations